These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 15710579)

  • 1. A mini-review on platelet refractoriness.
    Rebulla P
    Haematologica; 2005 Feb; 90(2):247-53. PubMed ID: 15710579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
    Xia WJ; Ye X; Tian LW; Xu XZ; Chen YK; Luo GP; Bei CH; Deng J; Santoso S; Fu YS
    Transfus Med; 2010 Aug; 20(4):269-74. PubMed ID: 20136782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alloimmunized patient: effective transfusion support and newer experimental approaches.
    Pamphilon DH
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):651-4. PubMed ID: 1450334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients refractory to platelet transfusion.
    Chockalingam P; Sacher RA
    J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and management of refractoriness to platelet transfusion.
    Schiffer CA
    Blood Rev; 2001 Dec; 15(4):175-80. PubMed ID: 11792118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for managing refractoriness to platelet transfusions.
    Dan ME; Schiffer CA
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients.
    Menitove JE; Duquesnoy RJ
    Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
    Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
    Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New paradigms in the management of alloimmune refractoriness to platelet transfusions.
    Vassallo RR
    Curr Opin Hematol; 2007 Nov; 14(6):655-63. PubMed ID: 17898571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet transfusion. Current techniques, remaining problems, and future prospects.
    Herman JH; Kamel HT
    Am J Pediatr Hematol Oncol; 1987; 9(3):272-86. PubMed ID: 3314551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of platelets and other transfusion products in patients with malignancy.
    Bayer WL; Bodensteiner DC; Tilzer LL; Adams ME
    Semin Thromb Hemost; 1992; 18(4):380-91. PubMed ID: 1470926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
    McVey M; Cserti-Gazdewich CM
    Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.